In addition to the Series D/D1 round of capital increase, the company has raised a total of approximately 1.57 billion yen through the confirmed AMED subsidy.
Preparations for domestic clinical trials for metastatic and recurrent HER2-negative breast cancer, including triple-negative breast cancer, have been progressing smoothly up to now, but with this latest funding, the company plans to begin preparations for clinical trials in the United States in parallel with the start of domestic clinical trials.